or Try an Advanced Search...

    Stage Biopharmaceutical Stocks List

    Symbol Grade Name % Change
    HCWB F HCW Biologics Inc. 0.91
    ALGS F Aligos Therapeutics, Inc. -2.53
    VRNA F Verona Pharma plc -1.69
    PULM F Pulmatrix, Inc. 3.14
    TRVN F Trevena, Inc. 0.52
    SGMO F Sangamo BioSciences, Inc. -5.39
    MNPR F Monopar Therapeutics Inc. 1.62
    KOD F Kodiak Sciences Inc -1.21
    LUMO F Lumos Pharma, Inc. 3.15
    NERV F Minerva Neurosciences, Inc -1.59
    View As Page of Charts
    Related Industries: Biotechnology Drug Manufacturers - General
    Related Stock Lists: Medicine Biotechnology Chronic Obstructive Pulmonary Disease Clinical Medicine Cystic Fibrosis Life Sciences Organ Systems Pulmonary Fibrosis Acute And Chronic Pain Acute Myeloid Leukemia Acute Pain Age Related Diseases Alcohol Alopecia Areata Analgesics Angiogenesis Angiology Antidepressants Antiviral Therapies Asthma

    Related ETFs - A few ETFs which own one or more of the above listed Stage Biopharmaceutical stocks.

    Symbol Grade Name Weight
    LABD F Direxion Daily S&P Biotech Bear 3X Shares 0.77
    SBIO C ALPS Medical Breakthroughs ETF 0.68
    BIS F ProShares UltraShort Nasdaq Biotechnology 0.35
    DWAS B PowerShares DWA SmallCap Technical Leaders Portfolio 0.27
    BTEC C Principal Healthcare Innovators Index ETF 0.1
    View all Stage Biopharmaceutical ETFs...
    Compare ETFs
    Compare SBIO to BIS Compare SBIO to BTEC Compare SBIO to DWAS

        Stage Biopharmaceutical Stocks Recent News

        Date Stock Title
        May 17 PULM Pulmatrix files for $95M mixed shelf
        May 17 MNPR Bears are Losing Control Over Monopar Therapeutics (MNPR), Here's Why It's a 'Buy' Now
        May 16 KOD Kodiak (KOD) Q1 Loss Narrower Than Expected, Pipeline in Focus
        May 16 ALGS After Plunging -13.71% in 4 Weeks, Here's Why the Trend Might Reverse for Aligos Therapeutics (ALGS)
        May 16 LUMO Lumos Pharma Inc (LUMO) Q1 2024 Earnings Call Transcript Highlights: Navigating Financial ...
        May 15 KOD Kodiak Sciences GAAP EPS of -$0.82 beats by $0.21
        May 15 HCWB HCW Biologics Reports First Quarter 2024 Financial Results and Business Highlights
        May 15 KOD Kodiak Sciences Announces Recent Business Highlights and First Quarter 2024 Financial Results
        May 15 LUMO Lumos Pharma, Inc. (LUMO) Q1 2024 Earnings Call Transcript
        May 15 PULM Pulmatrix Announces Peer-Reviewed Publication of Clinical Results for its Orally Inhaled DHE for Acute Migraine (PUR3100)
        May 15 TRVN Trevena GAAP EPS of -$0.36 beats by $0.11
        May 15 TRVN Trevena Reports First Quarter 2024 Results and Provides Business Update
        May 15 LUMO Lumos Pharma GAAP EPS of -$1.29 misses by $0.11, revenue of $0.17M misses by $0.13M
        May 14 LUMO Lumos Pharma Announces Positive End-of-Phase 2 Meeting with FDA and Reports First Quarter 2024 Financial Results
        May 14 LUMO Lumos Pharma Q1 2024 Earnings Preview
        May 14 KOD Kodiak Sciences dosing subjects in Phase III trial of diabetic retinopathy drug
        May 13 KOD Kodiak Sciences Announces Treatment of First Patients in Phase 3 GLOW2 Study of Tarcocimab Tedromer in Diabetic Retinopathy
        Related Industries: Biotechnology Drug Manufacturers - General
        Related Stock Lists: Medicine Biotechnology Chronic Obstructive Pulmonary Disease Clinical Medicine Cystic Fibrosis Life Sciences Organ Systems Pulmonary Fibrosis Acute And Chronic Pain Acute Myeloid Leukemia Acute Pain Age Related Diseases Alcohol Alopecia Areata Analgesics Angiogenesis Angiology Antidepressants Antiviral Therapies Asthma
        Stage Biopharmaceutical

        Browse All Tags